Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

Accepted/In Press date: 17 November 2023

e-pub ahead of print date: 21 November 2023

Published date: 15 December 2023

Additional Information: Funding Information: M.D.S. acted on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM. He received no personal financial payment for this work. Subsequent to this study MDS is employed by Moderna Biotech UK and holds equity in this company. S.N.F. acts on behalf of University Hospital Southampton National Health Service (NHS) Foundation Trust as an investigator or providing consultative advice, or both, on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck, and Valneva. He receives no personal financial payment for this work. M.R. has provided post-marketing surveillance reports on vaccines for Pfizer and GlaxoSmithKline for which a cost recovery charge is made. All other authors declare no competing interests. M.C. and S.L. are funded by US Food and Drug Administration Medical Countermeasures Initiative, contract 75F40120C00085. Funding Information: This research is funded by the NIHR PRP (PR-R17-0916-22001, CV220-036) and HSC R&D Division, Public Health Agency Ref: COM/5596/20 with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) and the Huo Family Foundation. The investigators express their gratitude for the contribution of all trial participants. This research is funded by the National Institute for Health Research (NIHR) Policy Research Program and the UK Research and Innovation (UKRI) Medical Research Council (PR-R17-0916-22001, CV220-036, CV220-036/1). The research is supported by the NIHR Oxford Clinical Research Facility and Biomedical Research Centre, the NIHR Clinical Research Network, and the NIHR funded National Immunisation Schedule Evaluation Consortium (PR-R17-0916-22001). The SARS-CoV2 S1 antigen used in the oral fluid assay was produced and gifted by Peter Cherepanov at The Francis Crick Institute. The study sponsor is the University of Oxford The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. M.D.S. N.A. G.A. and J.L.B. conceived the study and M.D.S. is the chief investigator. M.D.S. N.A. J.L.B. G.A. M.R. and H.R. contributed to the protocol and design of the study. P.K.A. E.P. I.V. E.M. N.L.D. S.M. and H.R. led the implementation of the study. E.G. S.N.F. S.H. C.M. M.R. F.S. S.O. T.L. D.P.J.T. M.R. S.O. P.J.T. H.C. S.J.D. and P.K. contributed to the adaptation of the STORY study design during the SARS-CoV-2 pandemic, to the implementation of the study in the context of the pandemic and acquisition of data. C.R. C.T. C.W. and T.W. provided data and assisted in sample selection from the COVID warriors study for additional testing. K.E.B. E.L. R.B. K.H. J.P. S.I. J.S. S.L. and M.C. were responsible for performing laboratory testing. K.T. and H.R. conducted the statistical analysis and verified the underlying data under the supervision of M.V. H.R. K.T. and M.D.S. drafted the initial version of the paper, which was critically reviewed by all other authors for important intellectual content. All other authors contributed to the implementation and data collection. All authors reviewed and approved the final report. M.D.S. acted on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM. He received no personal financial payment for this work. Subsequent to this study MDS is employed by Moderna Biotech UK and holds equity in this company. S.N.F. acts on behalf of University Hospital Southampton National Health Service (NHS) Foundation Trust as an investigator or providing consultative advice, or both, on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck, and Valneva. He receives no personal financial payment for this work. M.R. has provided post-marketing surveillance reports on vaccines for Pfizer and GlaxoSmithKline for which a cost recovery charge is made. All other authors declare no competing interests. M.C. and S.L. are funded by US Food and Drug Administration Medical Countermeasures Initiative, contract 75F40120C00085. Funding Information: This research is funded by the NIHR PRP ( PR-R17-0916-22001 , CV220-036 ) and HSC R&D Division , Public Health Agency Ref: COM/5596/20 with contributions from UKRI /NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) and the Huo Family Foundation . Funding Information: The investigators express their gratitude for the contribution of all trial participants. This research is funded by the National Institute for Health Research (NIHR) Policy Research Program and the UK Research and Innovation (UKRI) Medical Research Council ( PR-R17-0916-22001 , CV220-036 , CV220-036/1 ). The research is supported by the NIHR Oxford Clinical Research Facility and Biomedical Research Centre , the NIHR Clinical Research Network, and the NIHR funded National Immunisation Schedule Evaluation Consortium ( PR-R17-0916-22001 ). The SARS-CoV2 S1 antigen used in the oral fluid assay was produced and gifted by Peter Cherepanov at The Francis Crick Institute. The study sponsor is the University of Oxford The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Publisher Copyright: © 2023 The Authors

Keywords: Health sciences, Immunology, Medical specialty, Medicine, Virology

Local EPrints ID: 485787

URI: http://eprints.soton.ac.uk/id/eprint/485787

DOI: doi:10.1016/j.isci.2023.108500

ISSN: 2589-0042

PURE UUID: 32500461-b99f-4c11-a6df-58afd8950693

ORCID for Saul N. Faust: orcid.org/0000-0003-3410-7642

Date deposited: 19 Dec 2023 17:39

Last modified: 18 Mar 2024 03:04